目的 探討注射用紅花黃色素聯(lián)合注射用鹽酸替羅非班治療急性冠狀動(dòng)脈綜合征的安全性和有效性。方法 選取2015年9月—2016年9月平煤神馬醫(yī)療集團(tuán)總醫(yī)院心血管內(nèi)科收治的急性冠狀動(dòng)脈綜合征患者197例，隨機(jī)分成對(duì)照組（98例）和治療組（99例）。對(duì)照組靜脈滴注注射用鹽酸替羅非班，12.5 mg加入到0.9%氯化鈉注射液500 mL中，起始劑量為0.4 μg/(kg·min)，靜脈滴注1 h，然后以0.1 μg/(kg·min)的劑量進(jìn)行維持治療72 h。治療組在對(duì)照組基礎(chǔ)上靜脈滴注注射用紅花黃色素，100 mg加入到0.9%氯化鈉注射液250 mL中，1次/d。所有患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組的心功能指標(biāo)、超敏C反應(yīng)蛋白（hs-CRP）、白細(xì)胞介素-6（IL-6）、基質(zhì)金屬蛋白酶-9（MMP-9）、不良心血管事件情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為85.71%、94.95%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組左心室舒張末期內(nèi)徑（LVEDD）、左心室收縮末期內(nèi)徑（LVESD）、左房舒張末期內(nèi)徑（LADD）和左室射血分?jǐn)?shù)（LVEF）均顯著升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的升高程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組hs-CRP、IL-6和MMP-9水平顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療1個(gè)月后，對(duì)照組和治療組不良心血管事件發(fā)生率分別為17.35%、6.06%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 注射用紅花黃色素聯(lián)合注射用鹽酸替羅非班治療急性冠狀動(dòng)脈綜合征具有較好的臨床療效，可改善心功能指標(biāo)，調(diào)節(jié)hs-CRP、IL-6和MMP-9水平，降低不良心血管事件，安全性較好，具有一定的臨床推廣價(jià)值。

Objective To explore the safety and efficacy of Safflower yellow for injection combined with Tirofiban Hydrochloride for injection in treatment of acute coronary syndrome. Methods Patients (197 cases) with cerebral infarction in Department of Cardiovascular Medicine of Pingdingshan Shenma Medical Group General Hospital from September 2015 to September 2016 were randomly divided into the control group (98 cases) and the treatment group (99 cases). Patients in the control group were iv administered with Tirofiban Hydrochloride for injection, 12.5 mg added into normal saline 500 mL, starting dosage 0.4 μg/(kg·min) for 1 h, then maintenance dosage 0.1μg/(kg·min) for 72 h. Patients in the treatment group were iv administered with Safflower yellow for injection on the basis of the control group, 100 mg added into normal saline 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and heart function indexes, hs-CRP, IL-6, MMP-9, and adverse cardiovascular events in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 85.71% and 94.95%, respectively, and there was difference between two groups (P < 0.05). After treatment, LVEDD, LVESD, LADD, and LVEF in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of hs-CRP, IL-6, and MMP-9 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment for one month, the adverse cardiovascular events in the control and treatment groups were 17.35% and 6.06%, respectively, and there was difference between two groups (P < 0.05). Conclusion Safflower yellow for injection combined with Tirofiban Hydrochloride for injection has clinical curative effect in treatment of acute coronary syndrome, can improve heart function, regulate the levels of hs-CRP, IL-6, and MMP-9, and decrease adverse cardiovascular events, with good safety, which has a certain clinical application value.